Debt and Its Impacts on TB and HIV Investment
Public financing and domestic resources for health are straining under debt burdens as countries struggle to build up domestic revenues in the face of weak tax systems and volatile markets.
TAG Profoundly Disappointed and Outraged at Lack of Healthcare Protections
Treatment Action Group (TAG) is profoundly disappointed and outraged at the lack of healthcare protections for people living with and affected by HIV, tuberculosis (TB), and hepatitis C (HCV) in the bill to end the US government shutdown.
Governments and Donors Must Step Forward to Fund Global, Equitable Access to New TB Vaccines in Development
Treatment Action Group (TAG) welcomes the report published today by the World Health Organization TB Vaccine Accelerator Council on how to finance global, equitable access to new TB vaccines.
TB Representative Studies Rubric (TB RSR)
TAG and the Community Research Advisors Group (CRAG) are happy to introduce the TB Representative Studies Rubric (TB RSR), a new tool that community advisory boards (CABs) can use when designing and reviewing clinical trials protocols. The TB RSR is a 17-item questionnaire that assesses whether TB treatment trials include the types of people who get TB.
Treatment Action Group Statement on Suspension of TB Funding Over White House Gain-of-Function Fictions
Treatment Action Group (TAG) opposes in the strongest possible terms the suspension of at least 22 TB research awards by the National Institutes of Health (NIH) following a May 2025 White House executive order banning “gain-of-function” research.
An Activist’s Guide to Diagnostic Tools for Tuberculosis 2025
The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs.
2024 Annual Report
I’m proud to share with you TAG’s 2024 Annual Report. Last year already seems long ago with all the attacks on research and health care, domestic and international, which are currently taking place under the new administration...
WEBINAR: TB Treatment’s New Frontier: Orienting Community to Long-Acting Injectables for TB
On June 5, 2025, TAG and WHO cohosted a webinar orienting people to long-acting injectables for TB treatment and prevention. Long-acting Injectables (LAIs) have the potential to revolutionize treatment for TB and other infectious diseases.
2025 Comments Delivered at the WHO Director General’s TB Vaccine Accelerator Council
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 3rd meeting of the WHO Director-General’s TB Vaccine Accelerator Council on May 20, 2025 in Geneva, Switzerland.
U.S. Funding Cuts Threaten 39 Research Sites in South Africa Putting Scientific Advancements and Hard Won Progress Against TB and HIV at Risk
Lifesaving scientific research on prevention, testing, treatment and care for people living with HIV and tuberculosis (TB) in South Africa is under serious threat due to funding suspensions and grant terminations from the United States (US) government.